Caris & Co Initiates Coverage on Medtronic (MDT) with an Average Rating
More News related to MDT
- Citi Maintains a 'Buy' on Medtronic (MDT), Lowers Price Target
- Medtronic Launches New Medical Device in U.S. to Improve Treatment of Aortic Aneurysms
- Medtronic to Showcase Latest Aortic Repair Technology at International Vascular Surgery Meeting in New York
- David Moenning's Daily State of the Markets: 11/18
- Medtronic (MDT) Lowers FY09 Outlook
More News related to New Coverage
- Citi Initiates Coverage on US Soft Drink Makers
- William Blair Initiates Coverage on Data Networking Stocks
- Caris Starts Coverage on Ariba (ARBA), Concur (CNQR), salesforce.com (CRM), Taleo (TLEO)
- Oppenheimer Initiates Coverage on ViroPharma (VPHM)
- Oppenheimer Initiates Coverage on Cadence Pharmaceuticals (CADX) with an Outperform
Caris & Co initiates coverage on Medtronic (NYSE: MDT) with an Average. Price target $60.
Medtronic, Inc. (Medtronic) is a global player in medical technology, alleviating pain, restoring health, and extending life for millions of people around the world.
Related Categories
New CoverageStocks Mentioned
+1.94Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
